Pieter Gillard, Pieter Gillard, V. Huurman, V. Huurman, Bart Van Der Auwera, Bart Van Der Auwera, B. Decallonne, B. Decallonne, Kris Poppe, Kris Poppe, B. Roep, B. Roep, Frans Gorus, Frans Gorus, C. Mathieu, C. Mathieu, Daniel Pipeleers, Daniel Pipeleers, Bart Keymeulen, Bart Keymeulen
Objective: After an initially successful islet cell transplantation, a number of patients return to C-peptide-negativity and are therefore discontinued in immune suppressive therapy. Some were found to develop Graves' disease. Research design and methods: Immune suppressive therapy was stopped in 13 type 1 diabetic islet cell recipients who had received one course of antithymocyte globulin and maintenance doses of mycophenolate mofetil and a calcineurin inhibitor. None had a history of thyroid disease. Results: In 4 patients clinical Graves' hyperthyroidism was observed within 21 months after discontinuation, and 30 to 71 months after start of immune suppressive therapy. All four exhibited a pretransplant positivity for thyroid peroxidase (TPO)-autoantibodies while the nine others were TPO-negative pre- and posttransplantation. Conclusions: Type 1 diabetic recipients of islet cell grafts with pretransplant TPO-autoantibody positivity exhibit a high risk for developing Graves' hyperthyroidism after immune suppressive therapy is discontinued for a failing graft.
Gillard, P, Huurman, V, Van Der Auwera, B, Decallonne, B, Poppe, K, Roep, B, Gorus, F, Mathieu, C, Pipeleers, D & Keymeulen, B 2009, 'Graves' hyperthyroidism after stopping immune suppressive treatment in type 1 diabetic islet cell recipients with pretransplant TPO autoantibodies.', Diabetes Care, vol. 32, pp. 1817-1819. <http://care.diabetesjournals.org/content/32/10/1817.long>
Gillard, P., Huurman, V., Van Der Auwera, B., Decallonne, B., Poppe, K., Roep, B., Gorus, F., Mathieu, C., Pipeleers, D., & Keymeulen, B. (2009). Graves' hyperthyroidism after stopping immune suppressive treatment in type 1 diabetic islet cell recipients with pretransplant TPO autoantibodies. Diabetes Care, 32, 1817-1819. http://care.diabetesjournals.org/content/32/10/1817.long
@article{c94968f49fe143678925cfbc25087519,
title = "Graves' hyperthyroidism after stopping immune suppressive treatment in type 1 diabetic islet cell recipients with pretransplant TPO autoantibodies.",
abstract = "Objective: After an initially successful islet cell transplantation, a number of patients return to C-peptide-negativity and are therefore discontinued in immune suppressive therapy. Some were found to develop Graves' disease. Research design and methods: Immune suppressive therapy was stopped in 13 type 1 diabetic islet cell recipients who had received one course of antithymocyte globulin and maintenance doses of mycophenolate mofetil and a calcineurin inhibitor. None had a history of thyroid disease. Results: In 4 patients clinical Graves' hyperthyroidism was observed within 21 months after discontinuation, and 30 to 71 months after start of immune suppressive therapy. All four exhibited a pretransplant positivity for thyroid peroxidase (TPO)-autoantibodies while the nine others were TPO-negative pre- and posttransplantation. Conclusions: Type 1 diabetic recipients of islet cell grafts with pretransplant TPO-autoantibody positivity exhibit a high risk for developing Graves' hyperthyroidism after immune suppressive therapy is discontinued for a failing graft.",
keywords = "Graves, hyperthyroidism, type 1 diabetes",
author = "Pieter Gillard and V. Huurman and \{Van Der Auwera\}, Bart and B. Decallonne and Kris Poppe and B. Roep and Frans Gorus and C. Mathieu and Daniel Pipeleers and Bart Keymeulen",
year = "2009",
language = "English",
volume = "32",
pages = "1817--1819",
journal = "Diabetes Care",
issn = "0149-5992",
publisher = "American Diabetes Association Inc.",
}